• +1-646-491-9876
    • +91-20-67278686

    Search

    Schizophrenia Pipeline Review H1 2017

    Schizophrenia Pipeline Review H1 2017

    • Report Code ID: RW0001799308
    • Category Pharmaceuticals
    • No. of Pages 309
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Schizophrenia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H1 2017, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

    Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 12, 13, 22, 1, 54, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 9 and 2 molecules, respectively.

    Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 6
    Schizophrenia - Overview 7
    Schizophrenia - Therapeutics Development 8
    Schizophrenia - Therapeutics Assessment 24
    Schizophrenia - Companies Involved in Therapeutics Development 36
    Schizophrenia - Drug Profiles 73
    Schizophrenia - Dormant Projects 274
    Schizophrenia - Discontinued Products 282
    Schizophrenia - Product Development Milestones 285
    Appendix 295

    List of Tables

    Number of Products under Development for Schizophrenia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by Adamed Sp z oo, H1 2017
    Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by AgeneBio Inc, H1 2017
    Schizophrenia - Pipeline by Alkermes Plc, H1 2017
    Schizophrenia - Pipeline by Angita BV, H1 2017
    Schizophrenia - Pipeline by Astellas Pharma Inc, H1 2017
    Schizophrenia - Pipeline by Athersys Inc, H1 2017
    Schizophrenia - Pipeline by Avanir Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by Avineuro Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by BCWorld Pharm Co Ltd, H1 2017
    Schizophrenia - Pipeline by BioCrea GmbH, H1 2017
    Schizophrenia - Pipeline by BioHealthonomics Inc, H1 2017
    Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Schizophrenia - Pipeline by Braeburn Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Schizophrenia - Pipeline by Critical Pharmaceuticals Ltd, H1 2017
    Schizophrenia - Pipeline by Curemark LLC, H1 2017
    Schizophrenia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Schizophrenia - Pipeline by Delpor Inc, H1 2017
    Schizophrenia - Pipeline by Denovo Biopharma LLC, H1 2017
    Schizophrenia - Pipeline by Evotec AG, H1 2017
    Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by Galenea Corp, H1 2017
    Schizophrenia - Pipeline by GeNeuro SA, H1 2017
    Schizophrenia - Pipeline by GlaxoSmithKline Plc, H1 2017
    Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
    Schizophrenia - Pipeline by GP Pharm SA, H1 2017
    Schizophrenia - Pipeline by GW Pharmaceuticals Plc, H1 2017
    Schizophrenia - Pipeline by H. Lundbeck A/S, H1 2017
    Schizophrenia - Pipeline by Heptares Therapeutics Ltd, H1 2017
    Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017
    Schizophrenia - Pipeline by Indivior Plc, H1 2017
    Schizophrenia - Pipeline by Insys Therapeutics Inc, H1 2017
    Schizophrenia - Pipeline by IntelGenx Corp, H1 2017
    Schizophrenia - Pipeline by Intra-Cellular Therapies Inc, H1 2017
    Schizophrenia - Pipeline by Johnson & Johnson, H1 2017
    Schizophrenia - Pipeline by JT Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by KemPharm Inc, H1 2017
    Schizophrenia - Pipeline by Kowa Company Ltd, H1 2017
    Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi SA, H1 2017
    Schizophrenia - Pipeline by Lead Discovery Center GmbH, H1 2017
    Schizophrenia - Pipeline by Lohocla Research Corp, H1 2017
    Schizophrenia - Pipeline by Luye Pharma Group Ltd, H1 2017
    Schizophrenia - Pipeline by Mapi Pharma Ltd, H1 2017
    Schizophrenia - Pipeline by Merck & Co Inc, H1 2017
    Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
    Schizophrenia - Pipeline by Neurocrine Biosciences Inc, H1 2017
    Schizophrenia - Pipeline by NeurOp Inc, H1 2017
    Schizophrenia - Pipeline by Newron Pharmaceuticals SpA, H1 2017
    Schizophrenia - Pipeline by Omeros Corp, H1 2017
    Schizophrenia - Pipeline by Otsuka Holdings Co Ltd, H1 2017
    Schizophrenia - Pipeline by Peptron Inc, H1 2017
    Schizophrenia - Pipeline by Pfizer Inc, H1 2017
    Schizophrenia - Pipeline by Promentis Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by Ra Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by Richter Gedeon Nyrt, H1 2017
    Schizophrenia - Pipeline by Sage Therapeutics Inc, H1 2017
    Schizophrenia - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
    Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
    Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by Suven Life Sciences Ltd, H1 2017
    Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017
    Schizophrenia - Pipeline by Tetra Discovery Partners LLC, H1 2017
    Schizophrenia - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
    Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc, H1 2017
    Schizophrenia - Pipeline by Vitality Biopharma Inc, H1 2017
    Schizophrenia - Pipeline by VLP Therapeutics LLC, H1 2017
    Schizophrenia - Pipeline by Zogenix Inc, H1 2017
    Schizophrenia - Pipeline by Zysis Ltd, H1 2017
    Schizophrenia - Dormant Projects, H1 2017
    Schizophrenia - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Schizophrenia - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Schizophrenia - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Schizophrenia - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Schizophrenia - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Schizophrenia - Dormant Projects, H1 2017 (Contd..6) , H1 2017
    Schizophrenia - Dormant Projects, H1 2017 (Contd..7) , H1 2017
    Schizophrenia - Discontinued Products, H1 2017
    Schizophrenia - Discontinued Products, H1 2017 (Contd..1) , H1 2017
    Schizophrenia - Discontinued Products, H1 2017 (Contd..2) , H1 2017

    List of Figures

    Number of Products under Development for Schizophrenia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Acadia Pharmaceuticals Inc
    Adamed Sp z oo
    Aequus Pharmaceuticals Inc
    AgeneBio Inc
    Alkermes Plc
    Angita BV
    Astellas Pharma Inc
    Athersys Inc
    Avanir Pharmaceuticals Inc
    Avineuro Pharmaceuticals Inc
    BCWorld Pharm Co Ltd
    BioCrea GmbH
    BioHealthonomics Inc
    Boehringer Ingelheim GmbH
    Braeburn Pharmaceuticals Inc
    Bristol-Myers Squibb Company
    Critical Pharmaceuticals Ltd
    Curemark LLC
    Daewoong Pharmaceutical Co Ltd
    Delpor Inc
    Denovo Biopharma LLC
    Evotec AG
    F. Hoffmann-La Roche Ltd
    Fabre-Kramer Pharmaceuticals Inc
    Galenea Corp
    GeNeuro SA
    GlaxoSmithKline Plc
    Glenmark Pharmaceuticals Ltd
    GP Pharm SA
    GW Pharmaceuticals Plc
    H. Lundbeck A/S
    Heptares Therapeutics Ltd
    Hisamitsu Pharmaceutical Co Inc
    Indivior Plc
    Insys Therapeutics Inc
    IntelGenx Corp
    Intra-Cellular Therapies Inc
    Johnson & Johnson
    JT Pharmaceuticals Inc
    Karuna Pharmaceuticals Inc
    KemPharm Inc
    Kowa Company Ltd
    Laboratorios Farmaceuticos Rovi SA
    Lead Discovery Center GmbH
    Lohocla Research Corp
    Luye Pharma Group Ltd
    Mapi Pharma Ltd
    Merck & Co Inc
    Mitsubishi Tanabe Pharma Corp
    Neurocrine Biosciences Inc
    NeurOp Inc
    Newron Pharmaceuticals SpA
    Omeros Corp
    Otsuka Holdings Co Ltd
    Peptron Inc
    Pfizer Inc
    Promentis Pharmaceuticals Inc
    Ra Pharmaceuticals Inc
    Reviva Pharmaceuticals Inc
    Richter Gedeon Nyrt
    Sage Therapeutics Inc
    SK Biopharmaceuticals Co Ltd
    Sumitomo Dainippon Pharma Co Ltd
    Sunovion Pharmaceuticals Inc
    Suven Life Sciences Ltd
    Taisho Pharmaceutical Holdings Co Ltd
    Tetra Discovery Partners LLC
    Teva Pharmaceutical Industries Ltd
    Vanda Pharmaceuticals Inc
    Vitality Biopharma Inc
    VLP Therapeutics LLC
    Zogenix Inc
    Zysis Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//schizophrenia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//schizophrenia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//schizophrenia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments